advertisement
Abstract #52387 Published in IGR 15-1
Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-based Prospective Randomized Study
MacKy TAJournal of Glaucoma 2014; 23: 561-566
PURPOSE: To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC) fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population. METHODS: Patients with primary open angle glaucoma were randomized to receive either BTFC or TTFC. IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. The primary outcome measure was the mean change in IOP from baseline at each visit. Secondary outcome measures included the incidence of adverse events. RESULTS: Eighty patients (80 eyes) were included finally: 40 eyes in each group. Baseline mean IOPs were 24.78±3.53 and 25.26±3.51 mm Hg for BTFC and TTFC, respectively (P=0.344). Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001). BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001). Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mm Hg at 6 months (P=0.001) for BTFC and TTFC, respectively. IOPs at 2 weeks were ≤18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and ≤16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, ≤18 mm Hg in 38 (95%) versus 28 (70%) eyes and ≤16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001). CONCLUSION: Both drops provided effective IOP reduction that was greater and patients were more likely to achieve lower target pressures with BTFC than with TTFC.
*The Department of Ophthalmology, the Diagnostic Laser Unit, Kasr El Aini Hospital, Cairo University, El-Manial †Al Nour Eye Hospital, Cairo, Egypt.
Full articleClassification:
11.13.4 Betablocker and prostaglandin (Part of: 11 Medical treatment > 11.13 Combination therapy)
